Literature DB >> 3007872

Detection of HTLV-I (human T-cell lymphotropic virus, type I) proviral DNA in leukemic cells from a French patient with Sezary syndrome.

S Kaplanski, F Wong-Staal, C Farnarier-Seidel, M D Dodon, M M Golstein, E Jancovici, J Sayag, L Gazzolo, R Depieds.   

Abstract

Human T-lymphotropic type I (HTLV-I) proviral sequences were detected in leukemic cells of a patient living in Marseilles (south of France) and suffering from Sezary syndrome. He did not have any travel history outside France and did not receive blood transfusion or hepatitis B vaccination. This case of HTLV-I positive Sezary syndrome is the first one described outside the known endemic regions for HTLV-I. Moreover, this patient was found to be negative for viral antibodies. This observation should therefore stimulate new and thorough analysis of the association of this human retrovirus with leukemia and lymphoma in the Mediterranean region, both by seroepidemiological and molecular biology techniques.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007872     DOI: 10.1016/0145-2126(86)90066-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Polymerase chain reaction (PCR) amplification demonstrates the absence of human T-cell lymphotrophic virus (HTLV)-I specific pol sequences in peripheral T-cell lymphomas.

Authors:  T Henni; M Divine; P Gaulard; C Haioun; M Duc Dodon; M F Gourdin; L Desforges; M Goossens; F Reyes; J P Farcet
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

2.  Antibodies against retroviral core proteins in relation to disease outcome in patients with mycosis fungoides.

Authors:  A Ranki; K M Niemi; P Nieminen; K Krohn
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  Detection of HTLV-I proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas.

Authors:  I Anagnostopoulos; M Hummel; P Kaudewitz; H Herbst; O Braun-Falco; H Stein
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.